PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Hydroxychloroquine sulfate - Rheumatology indications

PAD Profile : Hydroxychloroquine sulfate - Rheumatology indications

Keywords :
Inflammatory disorders, RA, SLE, Systemic lupus erythematosus, Rheumatoid Arthritis, retinopathy eye screening
Brand Names Include :
Plaquenil

Traffic Light Status

Status 1 of 1.

Status :
Blue
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 October 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends a change in colour classification for hydroxychloroquine for the treatment of Rheumatology and dermatology conditions ((Rheumatoid Arthritis, Systemic Lupus Erythematosus and dermatology conditions caused or aggravated by sunlight). The traffic light status is now BLUE (with no information sheet) for this treatment for the above indications. Initiation by specialist only, with minimum of one month supply provided.
12 May 2022
Not Set

The Royal College of Ophthalmologists issued guidelines which recommend that all patients planning to take hydroxychloroquine long term i.e. over five years have a baseline examination in a hospital eye department ideally within six months, but definitely within 12 months. Patients should be referred for annual screening after five years of therapy and be reviewed annually thereafter whilst on therapy.

 

East Surrey Place: see narrative below from Feb 2020

Guildford & Waverley Place: A retinopathy screening service is provided by Frimley Health NHS Foundation Trust. A self-populating referral form is available on EMIS.

North West Surrey Place: A retinopathy screening service is provided by Frimley Health NHS Foundation Trust. A self-populating referral form is available on EMIS.

Guidelines from the Royal College of Ophthalmologists: Hydroxychloroquine-and-Chloroquine-Retinopathy-Monitoring-Guideline.pdf (rcophth.ac.uk)

21 February 2020
East Surrey CCG Medicines Programme Board

ESCCG and SASH LOCAL ARRANGEMENTS:

The Royal College of Ophthalmologists issued guidelines which recommend that all patients planning to take hydroxychloroquine long term i.e. over five years have a baseline examination in a hospital eye department ideally within six months, but definitely within 12 months. Patients should be referred for annual screening after five years of therapy and be reviewed annually thereafter whilst on therapy.

A retinopathy screening service is available at SASH NHS Trust and three referral letters have been developed for use - see template letters below

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More